1. Scrip
  2. >>Archive

US Capitol Capsule: Drug price 'yellow' signs: market canaries or lemons?

 
• By Donna Young

The "troubling" trends in the rising costs to US consumers of prescription drugs, including generics, is a big yellow warning sign the biopharmaceutical market is out of balance, largely due to a lack of transparency in how medicines are priced, insisted Dr Stephen Schondelmeyer, a professor of pharmaceutical management and economics and director of the PRIME Institute at the University of Minnesota.

The "troubling" trends in the rising costs to US consumers of prescription drugs, including generics, is a big yellow warning sign the biopharmaceutical market is out of balance, largely due to a lack of transparency in how medicines are priced, insisted Dr Stephen Schondelmeyer, a professor of pharmaceutical management and economics and director of the PRIME Institute at the University of Minnesota.

Without actual pricing data, it's not possible to make "true" value-based decisions, Dr Schondelmeyer told a Senate subcommittee last week, noting that while price may not be the "only" issue in a value-based decision, it's "always" a consideration (scripintelligence.com,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.